Issue 1 - San Antonio Breast Cancer Symposium

More documents

Recommendations

Info

12 AACR Outstanding Investigator Award The AACR Outstanding Investigator Award for Breast Cancer Research is presented to an investigator no more than 50 years of age whose novel and significant work has had, or may have, a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. This award, now in its second year, is funded by Susan G. Komen for the Cure®. Therapeutic Implications of the Molecular Portraits of Breast Cancer Thursday, December 10, 11:30 am Charles Perou, PhD Lineberger Cancer Center, Chapel Hill, NC Charles Perou, PhD, is an Associate Professor of Genetics and Pathology & Laboratory Medicine at the University of North Carolina at Chapel Hill. Dr Perou is a member of the Lineberger Comprehensive Cancer Center, the Carolina Center for Genome Sciences, and the Scientific Director of the UNC Genomics and Bioinformatics Core Facility. He received his PhD in Cellular and Molecular Biology from the Department of Pathology at the University of Utah (1996) where he cloned and characterized the human Chediak-Higashi syndrome gene. He next performed his postdoctoral training in the laboratory of David Botstein at Stanford University (1997-2000) where he began his genomic studies of human tumors using DNA microarrays. These genomic analyses resulted in the identification of novel subtypes of human breast tumors that predict patient survival times and response to therapy. Dr Perou’s laboratory at UNC is focused on using genomics, genetics, and animal models to decipher the underlying biology of the molecular subtypes of breast cancer, and then using this biological information to develop therapies that are specifically targeted against each of these distinct subtypes of breast cancer. He has identified at least 5 biologically distinct subtypes of breast tumor that are predictive of relapse, overall survival, and responsiveness to chemotherapy. Dr Perou will receive his award and present a lecture entitled Therapeutic Implications of the Molecular Portraits of Breast Cancer this morning at 11:30 am. Brinker Awards Go to Researchers in Endocrine Therapy Susan G. Komen for the Cure® Brinker Awards for Scientific Distinction The Susan G. Komen for the Cure® Brinker Awards for Scientific Distinction are presented to basic and clinical researchers who have made seminal advances in the fight against breast cancer. This year, the Brinker Awards will be presented to 1 clinical researcher and 2 basic science researchers who have made significant contributions in the area of endocrine therapy. Understanding SERM Actions in Breast Cancer Thursday, December 10, 4:30 pm Geoffrey L. Greene, PhD The University of Chicago, Chicago, IL Dr Green will receive an award for basic science research. Geoffrey L. Greene earned a PhD in chemistry from Northwestern University in 1974, and came to the University of Chicago the same year as a postdoctoral trainee in the Ben May Laboratory for Cancer Research. He joined the faculty as an assistant professor in 1980 and became a professor in 1991. Currently, Dr Greene is the Virginia and D.K. Ludwig Professor and associate director of the Ben May Department for Cancer Research, chair of the Committee on Cancer Biology, associate director of the Cancer Research Center, and co-director of the Ludwig Center for Metastasis Research at the University of Chicago. The overall goal of his research is to determine the molecular mechanisms by which female steroid hormones regulate development, differentiation, cellular proliferation, and survival in hormone-responsive tissues and cancers. Dr Greene has received a number of prestigious awards for his research contributions, and serves on several national committees, as well as journal editorial boards.
Issue 1, December 10, 2009 Brinker Awards Go to Researchers in Endocrine Therapy Susan G. Komen for the Cure® Brinker Awards for Scientific Distinction (continued) Genomics of Estrogen Receptor Signaling in Breast Cancer and Endocrine Resistance Thursday, December 10, 4:45 pm Benita katzenellenbogen, PhD University of Illinois-Urbana Champaign, Urbana, IL Benita S. Katzenellenbogen, PhD, will also receive an award for basic science research. Dr Katzenellenbogen, PhD, is the Swanlund Professor of Molecular and Integrative Physiology, Cell and Developmental Biology at the University of Illinois Urbana-Champaign. She is a world expert on nuclear hormone receptors, especially on estrogen receptors and their actions in breast cancer. Her work has elucidated fundamental aspects of structure-function relationships and mechanisms of action of the estrogen receptors, and has provided a framework for the development of anti-hormonal treatments that are used in breast cancer treatment and prevention. Dr Katzenellenbogen has trained many young investigators who have gone on to successful careers, and she has served on many important committees and review panels and as President of the Endocrine Society from 2000-2001. Her research contributions have been recognized by multiple prestigious awards and honors from professional societies and foundations. Getting the Best Out of Neoadjuvant Therapy Thursday, December 10, 5:00 pm Professor Ian Smith Royal Marsden Hospital, London, United Kingdom Professor Ian Smith is Professor of Cancer Medicine at the Institute of Cancer Research and the Royal Marsden Hospital, London, where he is also the Head of the Breast Unit. His principal research interests have been in the biology and treatment of breast cancer and lung cancer, and in new drug development. He was involved in the early clinical development of several successful anti-cancer drugs, including letrozole and carboplatin. One of his main interests is in neoadjuvant and short-term preoperative treatments and in the molecular changes associated with these therapies. He is Chief Investigator of 2 international neoadjuvant endocrine therapy trials, IMPACT and IRESSA 223, and the UK Principal Investigator for several international multicenter adjuvant trials, including HERA (trastuzumab), BIG1-98 (letrozole), and ALTTO (lapatinib). He is the first chairman of the recently formed UK Breast Trials Intergroup and recent past chairman of the British Breast Group. He has also been Chairman of several national professional bodies, including the Association of the Cancer Physicians, the Royal College of Physicians Specialist Advisory Committee for Medical Oncology, and the NCRI Lung Cancer Clinical Studies Group. He is a member of numerous international cancer societies and has over 300 peer-reviewed publications. 13
Page 1 and 2: 1 Issue 1 December 10, 2009 “An i
Page 3 and 4: Speaker & Schedule Changes Thursday
Page 5 and 6: Abstract 112 Prediction of 10-year
Page 7 and 8: Abstract 41 PL + D (n=241) BV 7.5 m
Page 9 and 10: Abstract 710 A phase 2 study of tra
Page 11: SABCS Scholarship Recipients This y
Page 15 and 16: Issue 1, December 10, 2009 Supporte

Issue 1 - San Antonio Breast Cancer Symposium

Create successful ePaper yourself

Delete template?

Save as template?